TC11
Based on 3 publication(s) in Google Scholar
TC11 is a MCL1 degrader and apoptosis inducer. TC11 induces sustained CDK1 activation to phosphorylate and degrade MCL1, activates caspase-3, -8, and -9, inhibits centrosomal-regulatory NPM function to block centrosomal clustering, and triggers apoptosis independent of the cereblon pathway. TC11 blocks tumor cell proliferation in vitro and acts against tumor xenografts in vivo. TC11 can be used for the research of multiple myeloma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.55%
- CAS No.: 100823-03-8
- Formule: C20H22N2O2
- Masse moléculaire:322.40
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) TC11
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
Description
|
MCL1 |
CDK1 |
Caspase-9 |
Caspase-3 |
Caspase-8 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KMS-27 | IC50 |
8 μM
|
Antiproliferative activity against human KMS27 multiple myeloma cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 assay.
Antiproliferative activity against human KMS27 multiple myeloma cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 assay.
|
22761710 |
| KMS-34 | IC50 |
4 μM
|
Antiproliferative activity against human KMS34 multiple myeloma cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 assay.
Antiproliferative activity against human KMS34 multiple myeloma cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 assay.
|
22761710 |
| KMM-1 | IC50 |
7 μM
|
Antiproliferative activity against human KMM1 multiple myeloma cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 assay.
Antiproliferative activity against human KMM1 multiple myeloma cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 assay.
|
22761710 |
| KMS-11 | IC50 |
6 μM
|
Antiproliferative activity against human KMS11 multiple myeloma cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 assay.
Antiproliferative activity against human KMS11 multiple myeloma cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 assay.
|
22761710 |
| RPMI-8226 | IC50 |
7 μM
|
Antiproliferative activity against human RPMI8226 multiple myeloma cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 assay.
Antiproliferative activity against human RPMI8226 multiple myeloma cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 assay.
|
22761710 |
In Vitro
TC11 (1-30 μM; 48 h) induces dose-dependent cell death in human multiple myeloma KMS34 cells, with reduced viability observed at concentrations of 3 μM and above after 48 h[1].
TC11 (1-5 μM; 24 h) does not downregulate CRBN substrates IKZF1 and IKZF3 in human multiple myeloma KMS34 cells after 24 h of treatment at 1 or 5 μM[1].
TC11 (1-30 μM; 48 h) induces cell death in CRBN-silenced human multiple myeloma KMS21 cells in a CRBN-independent manner at concentrations of 1 μM and above after 48 h[1].
TC11 (0-50 μM; 72 h) potently inhibits proliferation of KMM1, KMS11, KMS27, KMS34, and RPMI8226 multiple myeloma cell lines with IC50 values ranging from 4-8 μM[2].
TC11 (1-2.5 μM; 72 h) shows that NPM knockdown increases the sensitivity of HeLa cells to TC11-induced cytotoxicity, with TC11 showing more potent viability reduction in NPM-depleted cells than control cells[2].
TC11 (5 μM; 24 h) induces M phase arrest in human multiple myeloma KMS34 cells at 5 μM after 24 h of treatment[1].
TC11 (5 μM; 12-48 h) activates cdc2, induces cleavage of caspase-3 and caspase-9, and downregulates MCL1 expression in human multiple myeloma KMS34 cells at 5 μM over a 12-48 h treatment period, leading to apoptosis after M phase arrest[1].
TC11 (5-50 μM; 6-96 h) induces caspase-dependent apoptosis in KMS34 multiple myeloma cells and HeLa cells, as evidenced by PARP cleavage, caspase activation, DNA fragmentation, and increased Annexin V-positive cell populations[2].
TC11 binds preferentially to monomeric NPM with a KD of 66 nM, compared to a weaker binding affinity for oligomeric NPM (KD = 0.13 mM)[2].
TC11 (5-20 μM; 6-24 h) induces concentration-dependent centrosomal clustering inhibition and multipolar spindle formation in mitotic HeLa cells, leading to multinucleation of interphase cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human multiple myeloma KMS34 cells
-
Concentration:1 μM, 3 μM, 10 μM, 30 μM
-
Incubation Time:48 h
-
Result:Dose-dependently reduced cell viability in KMS34 cells, with significant viability loss observed at 3, 10, and 30 μM.
-
Cell Line:human multiple myeloma KMS34 cells
-
Concentration:1 μM, 5 μM
-
Incubation Time:24 h
-
Result:Did not reduce the expression levels of CRBN substrates IKZF1 and IKZF3 compared to immunomodulatory imide drug-treated cells.
-
Cell Line:CRBN-silenced human multiple myeloma KMS21 cells
-
Concentration:1 μM, 3 μM, 10 μM, 30 μM
-
Incubation Time:48 h
-
Result:Induced cell death that was not inhibited in CRBN-silenced KMS21 cells, unlike lenalidomide-induced cell death which was suppressed.
-
Cell Line:human multiple myeloma KMS34 cells
-
Concentration:5 μM
-
Incubation Time:24 h
-
Result:Resulted in accumulation of KMS34 cells in M phase, with the M phase fraction increasing from 1.65% in vehicle-treated cells to 22.7% in TC11-treated cells.
-
Cell Line:human multiple myeloma KMS34 cells
-
Concentration:5 μM
-
Incubation Time:12-48 h
-
Result:Caused dephosphorylation of cdc2 at T14 (12 h post-treatment) and Y15 (36 h post-treatment).
Increased phosphorylation of cdc2 at T161 (12-48 h post-treatment).
Induced cleavage of caspase-3 (12 h post-treatment) and caspase-9 (24 h post-treatment).
Reduced MCL1 expression levels over the 12-48 h treatment period.
-
Cell Line:KMM1, KMS11, KMS27, KMS34, RPMI8226
-
Concentration:0-50 μM
-
Incubation Time:72 h
-
Result:Inhibited proliferation of all tested multiple myeloma cell lines, with IC50 values of 7 μM (KMM1), 6 μM (KMS11), 8 μM (KMS27), 4 μM (KMS34), and 7 μM (RPMI8226).
-
Cell Line:KMS34, HeLa
-
Concentration:0, 5, 25, 50 μM
-
Incubation Time:6 h; 24 h; 96 h
-
Result:Induced cleavage of PARP in KMS34 and HeLa cells after 24 h.
Induced cleavage of procaspase-3, 8, and 9 to their activated forms in KMS34 cells after 6 h.
Observed DNA fragmentation in KMS34 cells treated for 6 h.
Increased the percentage of early (Annexin V-positive/PI-negative) and late (Annexin V-positive/PI-positive) apoptotic KMS34 cells to 53.1% and 43.8%, respectively, after treatment with 50 μM for 96 h.
-
Cell Line:HeLa
-
Concentration:5, 10, 20 μM
-
Incubation Time:6 h; 24 h
-
Result:Induced concentration-dependent increases in the percentage of mitotic HeLa cells with multipolar spindles: ~50% at 5 μM, ~90% at 10 μM, and ~100% at 20 μM.
Caused most interphase HeLa cells to exhibit multiple nuclei after 24 h treatment with 5 μM.
-
Cell Line:NPM-knockdown HeLa cells, control HeLa cells
-
Concentration:1, 2.5 μM
-
Incubation Time:72 h
-
Result:Reduced viability of NPM-depleted HeLa cells to ~70% and ~20% at 1 μM and 2.5 μM, respectively.
Reduced viability of control siRNA-transfected HeLa cells to ~100% and ~60% at 1 μM and 2.5 μM, respectively, showing significantly reduced viability in NPM-depleted cells compared to control cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR/SCID (male, 5 weeks old, subcutaneous inoculation of 3×107 KMS34 multiple myeloma cells)[2]
-
Dosage:20 mg/kg
-
Administration:i.p.; twice with a 3-day interval
-
Result:Showed significant tumor volume suppression at 7 and 14 days post-treatment.
Increased cells with aggregated chromatin in treated tumor tissue.
Increased single-stranded DNA-positive apoptotic cells in treated tumor tissue.
Caused no mouse deaths or macroscopic toxicity.
Chemical Information
-
CAS No. 100823-03-8
-
Appearance Solid
-
Masse moléculaire 322.40
-
Formule C20H22N2O2
-
Color White to yellow
-
SMILES
O=C1N(C2=C(C(C)C)C=CC=C2C(C)C)C(C3=C1C=CC(N)=C3)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Mol Med Rep
CDK1‑induced regulation of p53 phosphorylation at Ser315 mediates cell cycle arrest and apoptosis of macrophages infected with clinical isolates of Mycobacterium tuberculosis. [Abstract]2026 Jan;33(1):44. PMID: 41268607 -
-
Tumour Virus Res
Ad-VT oncolytic adenovirus suppresses bladder cancer via cAMP-dependent AMPK-Raptor activation and G2/M arrest. [Abstract]2026 Jan 29:200337. PMID: 41619809
Solvant et solubilité
In Vitro:
DMSO : 50 mg/mL (155.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
Pureté et documentation
-
Fiche technique (298 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ichikawa D, et al. A phenylphthalimide derivative, TC11, induces apoptosis by degrading MCL1 in multiple myeloma cells. Biochemical and biophysical research communications. 2020 Jan 01;521(1):252-258. [Content Brief]
[2]. Shiheido H, et al. A phthalimide derivative that inhibits centrosomal clustering is effective on multiple myeloma. PloS one. 2012;7(6):e38878. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1017 mL | 15.5087 mL | 31.0174 mL | 77.5434 mL |
| 5 mM | 0.6203 mL | 3.1017 mL | 6.2035 mL | 15.5087 mL | |
| 10 mM | 0.3102 mL | 1.5509 mL | 3.1017 mL | 7.7543 mL | |
| 15 mM | 0.2068 mL | 1.0339 mL | 2.0678 mL | 5.1696 mL | |
| 20 mM | 0.1551 mL | 0.7754 mL | 1.5509 mL | 3.8772 mL | |
| 25 mM | 0.1241 mL | 0.6203 mL | 1.2407 mL | 3.1017 mL | |
| 30 mM | 0.1034 mL | 0.5170 mL | 1.0339 mL | 2.5848 mL | |
| 40 mM | 0.0775 mL | 0.3877 mL | 0.7754 mL | 1.9386 mL | |
| 50 mM | 0.0620 mL | 0.3102 mL | 0.6203 mL | 1.5509 mL | |
| 60 mM | 0.0517 mL | 0.2585 mL | 0.5170 mL | 1.2924 mL | |
| 80 mM | 0.0388 mL | 0.1939 mL | 0.3877 mL | 0.9693 mL | |
| 100 mM | 0.0310 mL | 0.1551 mL | 0.3102 mL | 0.7754 mL |